You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Genmab A/S disclosed that directors Martin Schultz and Mijke Zachariasse sold 617 shares and 351 shares, respectively, at DKK 3,540.87 on November 12, 2026.
Genmab A/S disclosed that Bradley Bailey sold 1,071 shares on 2026-11-11 at an aggregated price of DKK 3,602.98 on NASDAQ Copenhagen (XCSE).
Genmab A/S set share capital at DKK 62,570,683 and authorized its board through March 12, 2029 to increase capital by up to nominally DKK 6,600,000.
GenMab reported three positive phase three trials, including a 0.49 hazard ratio for frontline DLBCL and overall survival benefits for RENA and Pitocentumab, while retaining prior peak sales guidance.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GMAB
this stock
Genmab A/S
|
$31.67B | +66.8% | — | — | 1.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GMAB | -4.2% | +38.8% | +91.0% | -10.0% | +66.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -6.8% | +40.0% | +90.5% | -9.8% | +56.2% |
